After discontinuing a twice-daily medication dosage late last year, Pfizer announced on Thursday that it will be entering clinical trials for a modified, once-daily version of its weight-loss pill, danuglipron, later this year.
The new medication is a component of the second generation of weight-loss pills that are being developed by Novo Nordisk and Eli Lilly to provide patients with a more convenient option than injections.
Some analysts project that the weight-loss medication market—currently led by Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—will generate sales of over $150 billion annually by the early 2030s.
The pharmaceutical company did not specify a precise timetable for the drug’s development. Before moving the medication into clinical trials, it intends to assess the reformulated medication at various doses during the second half of this year.
Pfizer announced last year that it was concentrating on the creation of the new danuglipron version, abandoning the twice-daily form due to a high rate of side effects, including nausea and vomiting, which caused most patients to withdraw from the midstage trial.
Another daily medication for weight loss, called lotiglipron, was already discontinued because of safety concerns because some patients had elevated liver enzyme levels.
Also Read:
Biden Attends Washington Summit With Other NATO Leaders
The President Praises the UAE’s Ongoing Progress on Clean Energy Initiatives
